Rapid breathing relief patients can feel in 2 weeks and sustained through 1 year1,2
Baseline Blood EOS ≥300 cells/μL - QUEST (Secondary Endpoint)
- At Week 12 in patients with no biomarker requirement: 320 mL improvement from
baseline in pre-bronchodilator FEV1 with
DUPIXENT 200 mg + SOC (n=631) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CI: 80, 190 mL]) (QUEST, primary endpoint)1 - At Week 52 in patients with EOS ≥300 cells/μL: 480 mL improvement from
baseline in pre-bronchodilator FEV1 with DUPIXENT
300 mg + SOC (n=277) vs 230 mL with placebo + SOC (n=142) (QUEST, secondary endpoint)1 - In QUEST, a significant difference from placebo + SOC was not observed at 12 weeks in change
in pre-bronchodilator FEV1 in patients with baseline blood EOS ≥150 to <300
cells/μL taking DUPIXENT 300 mg + SOC and in patients with baseline
blood EOS <150 cells/μL taking DUPIXENT 200 mg or
300 mg + SOC1
Change in lung function over ~3 years4-6,c,d
Patients rolled into TRAVERSE OLE from QUEST (ITT) (secondary endpoint)
Mean
absolute
pre-BD
FEV1 (mL)
- 2150
- 2100
- 2050
- 2000
- 1950
- 1900
- 1850
- 1800
- 1750
- WEEKS:
- YEARS:
- 0
- 2
- 4
- 6
- 8
- 10
- 12
- 16
- 20
- 24
- 28
- 32
- 36
- 40
- 44
- 48
- 0
- 2
- 4
- 8
- 12
- 24
- 48
- 72
- 84
- 96
AT WEEK 96e
310 mL improvement in FEV1 at Week 96 in the DUPIXENT/DUPIXENT group (n=447) from baseline in the parent study of 1.78 L for patients enrolled from QUEST (secondary endpoint)6,7
330 mL improvement in FEV1 at Week 96 in the placebo/DUPIXENT group (n=219) from baseline in the parent study of 1.75 L for patients enrolled from QUEST4,5
There are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.
c1.78 L was the baseline FEV1 level from QUEST (n=633) compared with a placebo value of 1.75 L (n=321).4
dFEV1 was assessed in the exposed population (observed cases) using descriptive statistics. Week 0 (TRAVERSE) represents the start of the OLE, and Weeks refers to the time in OLE without regard to any time in any parent study.6
eImprovement in FEV1 at Week 96 (n=447) in the DUPIXENT/DUPIXENT group from baseline in the parent study of 1.78 L.
Results are descriptive.
BD, bronchodilator.
FeNO ≥25 ppba,b
450 mL IMPROVEMENT IN LUNG FUNCTION AT WEEK 12
from baseline in pre-bronchodilator FEV1 with DUPIXENT 300 mg + SOC (n=295) vs 210 mL with placebo + SOC (n=167) (LSM difference: 240 mL [95% CI: 160, 310 mL])1,3
- 440 mL improvement in lung function at Week 12 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg + SOC (n=288) vs 210 mL with placebo + SOC (n=157) (LSM difference: 230 mL [95% CI: 150, 310 mL])1,3
a Results are descriptive.
b The clinical interpretation of FeNO in asthma is not established and levels may be influenced by confounding factors.